Antibodies to truncated VEGF-D and uses thereof
AssigneeLudwig Institute for Cancer Research
InventorsMarc G. Achen, Steven Alan Stacker
Life of this patent
Estimating the term…
Abstract
The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
Claims20
A method of detecting VEGF-D in biological sample, comprising the step of contacting the sample with an antibody or an antibody labeled with a detectable label which specifically binds to a polypeptide comprising an amino acid sequence of SEQ ID NO:1, wherein said antibody is selected from the group consisting of a monoclonal antibody of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652, and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof or a humanized antibody thereof, and detecting the occurrence of binding of said antibody to VEGF-D.
A method of detecting VEGF-D in biological sample, comprising the step of contacting the sample with an antibody or an antibody labeled with a detectable label which interferes with an activity of VEGF-D mediated by a VEGF receptor-2 or VEGF receptor-3, wherein said antibody is selected from the group consisting of a monoclonal antibody of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652, and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof or a humanized antibody thereof, and detecting the occurrence of binding of said antibody to VEGF-D.
Dependencies are inferred from the claim text.